Advertisement
U.S. markets open in 6 hours 25 minutes
Advertisement

Aptevo Therapeutics Inc. (APVO)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Visitors trend2W10W9M
0.1790-0.0053 (-2.88%)
At close: 04:00PM EST
0.1900 +0.01 (+6.15%)
After hours: 07:38PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Performance Outlook
Previous Close0.1843
Open0.1900
Bid0.0000 x 900
Ask0.0000 x 3200
Day's Range0.1700 - 0.1949
52 Week Range0.1520 - 7.2000
Volume228,537
Avg. Volume504,533
Market Cap3.153M
Beta (5Y Monthly)5.24
PE Ratio (TTM)N/A
EPS (TTM)-2.4400
Earnings DateNov 14, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.38
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for APVO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Aptevo Therapeutics Inc.
    Analyst Report: Gilead Sciences, Inc.Gilead Sciences is a biopharmaceutical company that researches, develops, and sells therapies for treating HIV, hepatitis B, hepatitis C, and certain cancers. In October 2020, Gilead's Veklury (remdesivir) became the first approved treatment for COVID-19 in the U.S. Founded in 1987, the company is located in Foster City, California. It has operations in more than 35 countries and approximately 18,000 employees.
    Rating
    Fair Value
    Economic Moat
    20 hours agoArgus Research
View more
  • ACCESSWIRE

    Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update

    The Company's ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Continues to ProgressPlanning for APVO436 Phase 2 Trial Initiation in Both Relapsed/Refractory and Frontline AML OngoingExtended Cash Runway with $7 Million in Funding ...

  • ACCESSWIRE

    Aptevo to Present at Bio-Europe Conference

    SEATTLE, WA / ACCESSWIRE / November 1, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, ...

  • ACCESSWIRE

    Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update

    Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ended June 30, 2023 and provided a business update, including duration of remission (DOR) data for its lead clinical candidate, APVO436.